Gregory Kinney
Concepts (460)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 67 | 2026 | 926 | 6.700 |
Why?
| | Smoking | 35 | 2026 | 1478 | 2.250 |
Why?
| | Smokers | 19 | 2026 | 139 | 1.860 |
Why?
| | Coronary Artery Disease | 28 | 2025 | 751 | 1.780 |
Why?
| | Tomography, X-Ray Computed | 46 | 2026 | 2766 | 1.750 |
Why?
| | Pulmonary Emphysema | 14 | 2025 | 276 | 1.470 |
Why?
| | Diabetes Mellitus, Type 1 | 38 | 2025 | 3930 | 1.440 |
Why?
| | Cannabis | 10 | 2025 | 519 | 1.340 |
Why?
| | Forced Expiratory Volume | 28 | 2026 | 451 | 1.270 |
Why?
| | Spirometry | 19 | 2026 | 234 | 1.110 |
Why?
| | Bronchiectasis | 7 | 2023 | 115 | 0.940 |
Why?
| | Calcinosis | 17 | 2015 | 231 | 0.930 |
Why?
| | Lung | 24 | 2026 | 4119 | 0.850 |
Why?
| | Dronabinol | 4 | 2024 | 250 | 0.810 |
Why?
| | Respiratory Function Tests | 11 | 2021 | 543 | 0.790 |
Why?
| | Middle Aged | 103 | 2026 | 36359 | 0.780 |
Why?
| | Hyperlipidemias | 2 | 2023 | 120 | 0.780 |
Why?
| | Disease Progression | 29 | 2026 | 2857 | 0.760 |
Why?
| | Diabetic Ketoacidosis | 3 | 2022 | 212 | 0.750 |
Why?
| | Marijuana Smoking | 3 | 2022 | 248 | 0.730 |
Why?
| | Cannabinoids | 5 | 2024 | 181 | 0.730 |
Why?
| | Cardiovascular System | 1 | 2023 | 137 | 0.720 |
Why?
| | Cardiovascular Diseases | 7 | 2024 | 2218 | 0.660 |
Why?
| | Cigarette Smoking | 4 | 2026 | 103 | 0.640 |
Why?
| | Diabetes Mellitus, Type 2 | 6 | 2026 | 2623 | 0.640 |
Why?
| | Risk Factors | 43 | 2026 | 10840 | 0.640 |
Why?
| | Female | 124 | 2026 | 79080 | 0.630 |
Why?
| | Diabetic Angiopathies | 11 | 2016 | 265 | 0.630 |
Why?
| | Aged | 58 | 2026 | 26251 | 0.620 |
Why?
| | Male | 114 | 2026 | 73014 | 0.620 |
Why?
| | Volatilization | 1 | 2019 | 45 | 0.610 |
Why?
| | Humans | 150 | 2026 | 145625 | 0.610 |
Why?
| | Cohort Studies | 36 | 2026 | 6045 | 0.600 |
Why?
| | Nebulizers and Vaporizers | 1 | 2019 | 63 | 0.600 |
Why?
| | Coronary Vessels | 8 | 2025 | 245 | 0.560 |
Why?
| | Prenatal Exposure Delayed Effects | 4 | 2026 | 662 | 0.530 |
Why?
| | Coronary Disease | 8 | 2025 | 380 | 0.530 |
Why?
| | Pulmonary Artery | 6 | 2026 | 1116 | 0.500 |
Why?
| | Depression | 6 | 2026 | 1566 | 0.500 |
Why?
| | Marijuana Abuse | 1 | 2019 | 215 | 0.490 |
Why?
| | Prospective Studies | 31 | 2026 | 8087 | 0.480 |
Why?
| | Genetic Predisposition to Disease | 12 | 2026 | 2455 | 0.470 |
Why?
| | Air Pollution | 1 | 2019 | 314 | 0.470 |
Why?
| | Vascular Calcification | 5 | 2019 | 109 | 0.470 |
Why?
| | Genome-Wide Association Study | 11 | 2026 | 1526 | 0.450 |
Why?
| | Risk Assessment | 9 | 2024 | 3678 | 0.450 |
Why?
| | 1-Alkyl-2-acetylglycerophosphocholine Esterase | 2 | 2016 | 24 | 0.450 |
Why?
| | Arthritis, Rheumatoid | 4 | 2025 | 1184 | 0.440 |
Why?
| | Lung Diseases, Interstitial | 4 | 2025 | 677 | 0.430 |
Why?
| | Adult | 59 | 2026 | 40821 | 0.420 |
Why?
| | Quantitative Trait Loci | 2 | 2026 | 388 | 0.400 |
Why?
| | Vital Capacity | 8 | 2025 | 293 | 0.370 |
Why?
| | Cannabidiol | 2 | 2024 | 142 | 0.340 |
Why?
| | Atherosclerosis | 4 | 2023 | 410 | 0.330 |
Why?
| | Longitudinal Studies | 10 | 2024 | 3005 | 0.330 |
Why?
| | Biomarkers | 13 | 2025 | 4329 | 0.330 |
Why?
| | Airway Obstruction | 2 | 2024 | 152 | 0.320 |
Why?
| | Emphysema | 2 | 2023 | 100 | 0.320 |
Why?
| | Walk Test | 3 | 2026 | 82 | 0.310 |
Why?
| | Prevalence | 13 | 2025 | 2852 | 0.310 |
Why?
| | Exercise Tolerance | 4 | 2026 | 288 | 0.300 |
Why?
| | Polymorphism, Single Nucleotide | 8 | 2026 | 2228 | 0.300 |
Why?
| | Cross-Sectional Studies | 17 | 2026 | 5875 | 0.280 |
Why?
| | Pectoralis Muscles | 3 | 2021 | 18 | 0.280 |
Why?
| | Lipoproteins | 3 | 2016 | 165 | 0.280 |
Why?
| | Marijuana Use | 3 | 2024 | 218 | 0.280 |
Why?
| | Albuminuria | 4 | 2016 | 190 | 0.270 |
Why?
| | Case-Control Studies | 15 | 2025 | 3633 | 0.270 |
Why?
| | Proportional Hazards Models | 7 | 2025 | 1318 | 0.270 |
Why?
| | Calcium | 7 | 2018 | 1181 | 0.270 |
Why?
| | Severity of Illness Index | 15 | 2023 | 2910 | 0.260 |
Why?
| | Metformin | 2 | 2021 | 328 | 0.260 |
Why?
| | Bronchi | 3 | 2022 | 263 | 0.250 |
Why?
| | Bronchodilator Agents | 2 | 2026 | 186 | 0.250 |
Why?
| | Blood Glucose | 7 | 2026 | 2357 | 0.250 |
Why?
| | United States | 14 | 2026 | 16041 | 0.250 |
Why?
| | Predictive Value of Tests | 11 | 2019 | 2097 | 0.240 |
Why?
| | Anxiety | 3 | 2025 | 1118 | 0.240 |
Why?
| | Uteroglobin | 1 | 2026 | 31 | 0.240 |
Why?
| | Young Adult | 15 | 2023 | 14240 | 0.230 |
Why?
| | Body Mass Index | 11 | 2024 | 2446 | 0.230 |
Why?
| | Logistic Models | 13 | 2025 | 2112 | 0.230 |
Why?
| | Follow-Up Studies | 12 | 2026 | 5397 | 0.230 |
Why?
| | Monitoring, Intraoperative | 3 | 2010 | 65 | 0.230 |
Why?
| | Tandem Mass Spectrometry | 2 | 2019 | 574 | 0.220 |
Why?
| | Adrenergic beta-Antagonists | 2 | 2017 | 252 | 0.220 |
Why?
| | Aged, 80 and over | 11 | 2025 | 8351 | 0.220 |
Why?
| | Genomic Structural Variation | 1 | 2025 | 13 | 0.220 |
Why?
| | Precision Medicine | 2 | 2026 | 462 | 0.220 |
Why?
| | Pulmonary Diffusing Capacity | 3 | 2023 | 78 | 0.220 |
Why?
| | Cause of Death | 2 | 2018 | 455 | 0.220 |
Why?
| | Hypnotics and Sedatives | 2 | 2019 | 221 | 0.210 |
Why?
| | Plaque, Atherosclerotic | 2 | 2023 | 60 | 0.210 |
Why?
| | Lumbar Vertebrae | 3 | 2020 | 259 | 0.210 |
Why?
| | Antidepressive Agents | 3 | 2019 | 234 | 0.210 |
Why?
| | Adrenal Insufficiency | 1 | 2025 | 31 | 0.210 |
Why?
| | Self Administration | 1 | 2025 | 121 | 0.210 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 2 | 2021 | 228 | 0.210 |
Why?
| | Quality of Life | 4 | 2021 | 3187 | 0.210 |
Why?
| | RNA Splicing | 1 | 2026 | 287 | 0.210 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2025 | 133 | 0.210 |
Why?
| | Birth Weight | 2 | 2024 | 521 | 0.210 |
Why?
| | Renal Insufficiency | 2 | 2016 | 172 | 0.210 |
Why?
| | Symptom Flare Up | 2 | 2021 | 37 | 0.200 |
Why?
| | C-Peptide | 1 | 2025 | 191 | 0.200 |
Why?
| | Vaping | 1 | 2025 | 81 | 0.200 |
Why?
| | Dyspnea | 5 | 2024 | 251 | 0.190 |
Why?
| | Polysomnography | 1 | 2024 | 239 | 0.190 |
Why?
| | Tomography, Emission-Computed | 1 | 2022 | 71 | 0.190 |
Why?
| | Hydrocortisone | 1 | 2025 | 303 | 0.190 |
Why?
| | Fibrinogen | 3 | 2014 | 181 | 0.180 |
Why?
| | Adiponectin | 4 | 2016 | 243 | 0.180 |
Why?
| | Population Health | 1 | 2023 | 44 | 0.180 |
Why?
| | Multimorbidity | 1 | 2023 | 65 | 0.180 |
Why?
| | Limit of Detection | 2 | 2019 | 92 | 0.180 |
Why?
| | Phenotype | 6 | 2025 | 3186 | 0.180 |
Why?
| | Organ Size | 5 | 2025 | 463 | 0.180 |
Why?
| | Propofol | 2 | 2021 | 86 | 0.180 |
Why?
| | Umbilical Cord | 2 | 2021 | 92 | 0.180 |
Why?
| | Gene Expression Profiling | 2 | 2026 | 1790 | 0.180 |
Why?
| | Ketosis | 1 | 2022 | 12 | 0.180 |
Why?
| | Cystatin C | 3 | 2011 | 65 | 0.170 |
Why?
| | Cholesterol | 4 | 2011 | 410 | 0.170 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2023 | 102 | 0.170 |
Why?
| | Molecular Epidemiology | 2 | 2019 | 74 | 0.170 |
Why?
| | Models, Genetic | 1 | 2024 | 537 | 0.170 |
Why?
| | Protective Agents | 1 | 2021 | 43 | 0.170 |
Why?
| | Walking | 1 | 2026 | 544 | 0.170 |
Why?
| | Neurodegenerative Diseases | 1 | 2023 | 147 | 0.170 |
Why?
| | Sarcopenia | 1 | 2022 | 92 | 0.170 |
Why?
| | Hand Strength | 2 | 2022 | 145 | 0.170 |
Why?
| | Artificial Intelligence | 2 | 2023 | 385 | 0.160 |
Why?
| | Self Report | 3 | 2021 | 869 | 0.160 |
Why?
| | Hallucinogens | 1 | 2023 | 112 | 0.160 |
Why?
| | Antirheumatic Agents | 1 | 2023 | 309 | 0.160 |
Why?
| | Glucocorticoids | 1 | 2025 | 536 | 0.160 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2021 | 115 | 0.160 |
Why?
| | Proteome | 1 | 2025 | 520 | 0.160 |
Why?
| | C-Reactive Protein | 2 | 2014 | 427 | 0.160 |
Why?
| | Foraminotomy | 1 | 2020 | 1 | 0.160 |
Why?
| | Muscular Atrophy | 1 | 2021 | 87 | 0.160 |
Why?
| | Paresthesia | 1 | 2020 | 14 | 0.150 |
Why?
| | Cognitive Dysfunction | 1 | 2026 | 479 | 0.150 |
Why?
| | Hepatitis C | 1 | 2023 | 250 | 0.150 |
Why?
| | 2-Propanol | 1 | 2019 | 20 | 0.150 |
Why?
| | Osteoporosis | 1 | 2022 | 239 | 0.150 |
Why?
| | Pulmonary Heart Disease | 1 | 2019 | 7 | 0.150 |
Why?
| | Lumbosacral Region | 1 | 2020 | 58 | 0.150 |
Why?
| | Foam Cells | 1 | 2019 | 17 | 0.150 |
Why?
| | Genetic Markers | 2 | 2019 | 337 | 0.150 |
Why?
| | Hyperostosis | 1 | 2019 | 5 | 0.150 |
Why?
| | B-Lymphocytes | 1 | 2025 | 884 | 0.150 |
Why?
| | Delirium | 1 | 2021 | 106 | 0.150 |
Why?
| | Calibration | 1 | 2019 | 154 | 0.150 |
Why?
| | Regression Analysis | 6 | 2022 | 994 | 0.150 |
Why?
| | Diabetic Nephropathies | 2 | 2016 | 320 | 0.150 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2019 | 175 | 0.140 |
Why?
| | Carbon Monoxide | 1 | 2019 | 82 | 0.140 |
Why?
| | Sex Factors | 6 | 2026 | 2101 | 0.140 |
Why?
| | Surface Properties | 1 | 2019 | 383 | 0.140 |
Why?
| | Diabetes Complications | 2 | 2010 | 219 | 0.140 |
Why?
| | Anti-Anxiety Agents | 1 | 2019 | 46 | 0.140 |
Why?
| | Multifactorial Inheritance | 3 | 2025 | 242 | 0.140 |
Why?
| | Proteomics | 1 | 2025 | 1202 | 0.130 |
Why?
| | Adipose Tissue | 2 | 2017 | 641 | 0.130 |
Why?
| | Heart Ventricles | 2 | 2020 | 762 | 0.130 |
Why?
| | Polymorphism, Genetic | 3 | 2011 | 611 | 0.130 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2019 | 198 | 0.130 |
Why?
| | Insulin Resistance | 4 | 2017 | 1247 | 0.130 |
Why?
| | Drug Overdose | 1 | 2022 | 376 | 0.130 |
Why?
| | Factor Analysis, Statistical | 1 | 2018 | 295 | 0.130 |
Why?
| | Linear Models | 6 | 2019 | 847 | 0.130 |
Why?
| | Population Surveillance | 1 | 2021 | 477 | 0.130 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2025 | 697 | 0.130 |
Why?
| | Urine | 1 | 2017 | 63 | 0.130 |
Why?
| | Hospitalization | 2 | 2026 | 2468 | 0.130 |
Why?
| | Vascular Remodeling | 1 | 2019 | 208 | 0.130 |
Why?
| | Sleep | 1 | 2024 | 896 | 0.130 |
Why?
| | Environmental Monitoring | 1 | 2019 | 346 | 0.130 |
Why?
| | Gene Expression Regulation | 1 | 2026 | 2591 | 0.120 |
Why?
| | Chronic Disease | 1 | 2023 | 1824 | 0.120 |
Why?
| | Evoked Potentials, Somatosensory | 3 | 2015 | 39 | 0.120 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2017 | 44 | 0.120 |
Why?
| | Sexual and Gender Minorities | 1 | 2021 | 268 | 0.120 |
Why?
| | Bronchitis, Chronic | 1 | 2016 | 16 | 0.120 |
Why?
| | Lung Diseases | 1 | 2023 | 787 | 0.120 |
Why?
| | Blood Pressure | 5 | 2023 | 1761 | 0.120 |
Why?
| | Prenatal Care | 1 | 2019 | 310 | 0.120 |
Why?
| | HIV Infections | 2 | 2023 | 3210 | 0.120 |
Why?
| | Pregnancy | 6 | 2026 | 7217 | 0.120 |
Why?
| | Obesity | 4 | 2022 | 3123 | 0.120 |
Why?
| | Plasma | 1 | 2017 | 222 | 0.110 |
Why?
| | Aortography | 1 | 2015 | 52 | 0.110 |
Why?
| | Surveys and Questionnaires | 9 | 2026 | 6050 | 0.110 |
Why?
| | Multivariate Analysis | 5 | 2019 | 1531 | 0.110 |
Why?
| | Comorbidity | 5 | 2021 | 1652 | 0.110 |
Why?
| | Intraoperative Neurophysiological Monitoring | 1 | 2015 | 32 | 0.110 |
Why?
| | Respiratory System | 1 | 2016 | 150 | 0.110 |
Why?
| | Dexmedetomidine | 1 | 2015 | 47 | 0.110 |
Why?
| | Spinal Fusion | 3 | 2020 | 264 | 0.110 |
Why?
| | Adiposity | 2 | 2022 | 531 | 0.110 |
Why?
| | Periodontal Diseases | 1 | 2015 | 62 | 0.110 |
Why?
| | Evoked Potentials, Motor | 2 | 2015 | 52 | 0.110 |
Why?
| | Whole Genome Sequencing | 2 | 2026 | 183 | 0.100 |
Why?
| | Respiratory Muscles | 1 | 2014 | 36 | 0.100 |
Why?
| | Lung Volume Measurements | 2 | 2026 | 44 | 0.100 |
Why?
| | Endothelium, Vascular | 1 | 2021 | 952 | 0.100 |
Why?
| | Evoked Potentials | 1 | 2015 | 132 | 0.100 |
Why?
| | Polycystic Ovary Syndrome | 1 | 2017 | 190 | 0.100 |
Why?
| | Body Composition | 4 | 2021 | 686 | 0.100 |
Why?
| | Subcutaneous Fat | 1 | 2014 | 79 | 0.100 |
Why?
| | Health Status | 2 | 2022 | 822 | 0.100 |
Why?
| | Heart | 1 | 2017 | 624 | 0.100 |
Why?
| | Machine Learning | 1 | 2019 | 590 | 0.100 |
Why?
| | Spine | 1 | 2015 | 184 | 0.100 |
Why?
| | Haplotypes | 2 | 2025 | 505 | 0.100 |
Why?
| | Up-Regulation | 1 | 2016 | 840 | 0.100 |
Why?
| | Pregnancy Complications | 1 | 2019 | 605 | 0.090 |
Why?
| | Sex Distribution | 5 | 2014 | 379 | 0.090 |
Why?
| | Brain | 1 | 2025 | 2981 | 0.090 |
Why?
| | Orthopedic Procedures | 1 | 2015 | 252 | 0.090 |
Why?
| | Incidence | 4 | 2024 | 2910 | 0.090 |
Why?
| | Aorta | 1 | 2015 | 440 | 0.090 |
Why?
| | Colorado | 6 | 2021 | 4588 | 0.090 |
Why?
| | Blood Vessels | 1 | 2013 | 164 | 0.090 |
Why?
| | Prognosis | 5 | 2024 | 4331 | 0.090 |
Why?
| | Retrospective Studies | 9 | 2026 | 17291 | 0.090 |
Why?
| | Triglycerides | 2 | 2011 | 527 | 0.090 |
Why?
| | Time Factors | 7 | 2024 | 7079 | 0.090 |
Why?
| | Imaging, Three-Dimensional | 1 | 2015 | 578 | 0.080 |
Why?
| | Reference Values | 4 | 2023 | 787 | 0.080 |
Why?
| | Haptoglobins | 1 | 2011 | 71 | 0.080 |
Why?
| | Radiography | 4 | 2016 | 856 | 0.080 |
Why?
| | Hypertension, Pulmonary | 1 | 2022 | 1957 | 0.080 |
Why?
| | Genotype | 4 | 2024 | 1866 | 0.080 |
Why?
| | Occupational Exposure | 1 | 2014 | 356 | 0.080 |
Why?
| | Registries | 1 | 2019 | 2382 | 0.080 |
Why?
| | Carotid Intima-Media Thickness | 2 | 2023 | 75 | 0.080 |
Why?
| | Electrodiagnosis | 1 | 2010 | 17 | 0.080 |
Why?
| | Adolescent | 6 | 2022 | 22451 | 0.080 |
Why?
| | Statistics, Nonparametric | 1 | 2011 | 423 | 0.080 |
Why?
| | Diagnostic Techniques, Neurological | 1 | 2009 | 11 | 0.080 |
Why?
| | Iliac Artery | 1 | 2010 | 52 | 0.080 |
Why?
| | Coma | 1 | 2009 | 39 | 0.080 |
Why?
| | Patient Education as Topic | 2 | 2005 | 769 | 0.080 |
Why?
| | Meningomyelocele | 1 | 2010 | 63 | 0.080 |
Why?
| | Hypertension | 5 | 2015 | 1270 | 0.070 |
Why?
| | Alcohol Drinking | 2 | 2009 | 847 | 0.070 |
Why?
| | Facial Nerve | 1 | 2009 | 35 | 0.070 |
Why?
| | Lymphatic Abnormalities | 1 | 2009 | 20 | 0.070 |
Why?
| | Uric Acid | 1 | 2010 | 167 | 0.070 |
Why?
| | Anesthesia, General | 2 | 2021 | 122 | 0.070 |
Why?
| | Aortic Diseases | 1 | 2010 | 124 | 0.070 |
Why?
| | Pediatric Obesity | 1 | 2017 | 635 | 0.070 |
Why?
| | Respiratory Physiological Phenomena | 2 | 2022 | 34 | 0.070 |
Why?
| | Asthma | 1 | 2021 | 1800 | 0.070 |
Why?
| | Sensitivity and Specificity | 3 | 2022 | 1992 | 0.070 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2009 | 50 | 0.070 |
Why?
| | Intraoperative Complications | 1 | 2010 | 154 | 0.070 |
Why?
| | Odds Ratio | 4 | 2014 | 1070 | 0.070 |
Why?
| | Airway Remodeling | 2 | 2021 | 63 | 0.070 |
Why?
| | Diet, Ketogenic | 1 | 2009 | 39 | 0.070 |
Why?
| | Asymptomatic Diseases | 2 | 2021 | 102 | 0.070 |
Why?
| | Anesthesia, Intravenous | 2 | 2021 | 23 | 0.070 |
Why?
| | Reproducibility of Results | 5 | 2017 | 3396 | 0.070 |
Why?
| | Proteinuria | 1 | 2009 | 103 | 0.070 |
Why?
| | Neurosurgical Procedures | 1 | 2010 | 207 | 0.070 |
Why?
| | Kidney | 1 | 2016 | 1491 | 0.070 |
Why?
| | Reproductive History | 1 | 2008 | 12 | 0.070 |
Why?
| | Coronary Angiography | 2 | 2014 | 325 | 0.070 |
Why?
| | Aorta, Thoracic | 1 | 2010 | 284 | 0.070 |
Why?
| | Angiotensin II Type 2 Receptor Blockers | 1 | 2007 | 7 | 0.070 |
Why?
| | Face | 1 | 2009 | 177 | 0.070 |
Why?
| | Cystatins | 1 | 2007 | 7 | 0.070 |
Why?
| | Spinal Cord | 1 | 2010 | 378 | 0.060 |
Why?
| | Age of Onset | 2 | 2025 | 557 | 0.060 |
Why?
| | Dietary Fats | 1 | 2009 | 307 | 0.060 |
Why?
| | Life Style | 1 | 2009 | 495 | 0.060 |
Why?
| | Heart Rate | 1 | 2010 | 844 | 0.060 |
Why?
| | Renin-Angiotensin System | 1 | 2007 | 80 | 0.060 |
Why?
| | Inflammation | 2 | 2021 | 2915 | 0.060 |
Why?
| | Apolipoproteins A | 1 | 2006 | 19 | 0.060 |
Why?
| | Apolipoproteins C | 1 | 2006 | 3 | 0.060 |
Why?
| | Kidney Diseases | 1 | 2010 | 427 | 0.060 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 1 | 2026 | 103 | 0.060 |
Why?
| | Iceland | 1 | 2025 | 11 | 0.060 |
Why?
| | Mortality | 2 | 2019 | 375 | 0.060 |
Why?
| | Contraception | 1 | 2008 | 170 | 0.060 |
Why?
| | Receptors, Interleukin-2 | 1 | 2005 | 64 | 0.060 |
Why?
| | Cluster Analysis | 2 | 2019 | 494 | 0.060 |
Why?
| | Organ Specificity | 1 | 2026 | 306 | 0.060 |
Why?
| | Child, Preschool | 4 | 2024 | 11888 | 0.060 |
Why?
| | Infant, Newborn | 3 | 2025 | 6449 | 0.060 |
Why?
| | Internationality | 2 | 2017 | 156 | 0.060 |
Why?
| | Propensity Score | 2 | 2019 | 370 | 0.060 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2010 | 448 | 0.060 |
Why?
| | Chi-Square Distribution | 3 | 2010 | 511 | 0.060 |
Why?
| | Receptors, IgG | 1 | 2005 | 77 | 0.050 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2025 | 83 | 0.050 |
Why?
| | Abdominal Wall | 1 | 2004 | 25 | 0.050 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2025 | 50 | 0.050 |
Why?
| | Protein Interaction Maps | 1 | 2024 | 54 | 0.050 |
Why?
| | Drug Repositioning | 1 | 2024 | 41 | 0.050 |
Why?
| | Pandemics | 2 | 2024 | 1700 | 0.050 |
Why?
| | Apolipoprotein C-III | 2 | 2019 | 11 | 0.050 |
Why?
| | Antihypertensive Agents | 2 | 2007 | 519 | 0.050 |
Why?
| | Amygdala | 1 | 2025 | 194 | 0.050 |
Why?
| | Laryngeal Nerves | 1 | 2023 | 7 | 0.050 |
Why?
| | Laryngeal Muscles | 1 | 2023 | 10 | 0.050 |
Why?
| | Sequence Analysis, RNA | 1 | 2026 | 441 | 0.050 |
Why?
| | Cholesterol, LDL | 1 | 2005 | 363 | 0.050 |
Why?
| | Glomerular Filtration Rate | 3 | 2016 | 743 | 0.050 |
Why?
| | Reflex | 1 | 2023 | 69 | 0.050 |
Why?
| | Glucose Clamp Technique | 2 | 2017 | 199 | 0.050 |
Why?
| | HLA Antigens | 1 | 2025 | 241 | 0.050 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2005 | 372 | 0.050 |
Why?
| | United Kingdom | 1 | 2024 | 376 | 0.050 |
Why?
| | Infant | 3 | 2025 | 10093 | 0.050 |
Why?
| | Nutrition Surveys | 1 | 2024 | 270 | 0.040 |
Why?
| | Antigens, CD | 1 | 2005 | 559 | 0.040 |
Why?
| | Herpesvirus 4, Human | 1 | 2023 | 172 | 0.040 |
Why?
| | Blood Platelets | 1 | 2005 | 380 | 0.040 |
Why?
| | Insulin | 3 | 2022 | 2524 | 0.040 |
Why?
| | Morbidity | 1 | 2022 | 317 | 0.040 |
Why?
| | Muscles | 1 | 2022 | 330 | 0.040 |
Why?
| | Radiography, Thoracic | 2 | 2014 | 174 | 0.040 |
Why?
| | Biological Variation, Population | 1 | 2021 | 22 | 0.040 |
Why?
| | Survival Analysis | 2 | 2017 | 1372 | 0.040 |
Why?
| | Hepacivirus | 1 | 2023 | 236 | 0.040 |
Why?
| | Plethysmography | 1 | 2021 | 104 | 0.040 |
Why?
| | Protective Factors | 1 | 2021 | 97 | 0.040 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 1 | 2021 | 26 | 0.040 |
Why?
| | Reaction Time | 2 | 2015 | 434 | 0.040 |
Why?
| | Breast Feeding | 1 | 2024 | 447 | 0.040 |
Why?
| | Mice | 3 | 2026 | 18266 | 0.040 |
Why?
| | Hospitals, Urban | 1 | 2021 | 140 | 0.040 |
Why?
| | Diskectomy, Percutaneous | 1 | 2020 | 1 | 0.040 |
Why?
| | Animals | 4 | 2026 | 38030 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2022 | 424 | 0.040 |
Why?
| | Diskectomy | 1 | 2020 | 23 | 0.040 |
Why?
| | Diabetes Mellitus | 1 | 2009 | 1101 | 0.040 |
Why?
| | Substance Abuse Detection | 1 | 2021 | 110 | 0.040 |
Why?
| | Models, Statistical | 1 | 2024 | 667 | 0.040 |
Why?
| | Child Development | 1 | 2024 | 481 | 0.040 |
Why?
| | Hospitals, Pediatric | 2 | 2017 | 561 | 0.040 |
Why?
| | Oligodeoxyribonucleotides, Antisense | 1 | 2019 | 8 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2014 | 1293 | 0.040 |
Why?
| | rab4 GTP-Binding Proteins | 1 | 2019 | 7 | 0.040 |
Why?
| | Computer Simulation | 1 | 2024 | 1014 | 0.040 |
Why?
| | Cytochrome P-450 CYP2B6 | 1 | 2019 | 9 | 0.040 |
Why?
| | Cytochrome P450 Family 2 | 1 | 2019 | 12 | 0.040 |
Why?
| | Hippocampus | 1 | 2025 | 986 | 0.040 |
Why?
| | Administration, Inhalation | 1 | 2021 | 567 | 0.040 |
Why?
| | Homosexuality, Male | 1 | 2021 | 231 | 0.040 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2019 | 45 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2019 | 89 | 0.040 |
Why?
| | Multidetector Computed Tomography | 1 | 2019 | 40 | 0.040 |
Why?
| | Treatment Outcome | 3 | 2021 | 11744 | 0.040 |
Why?
| | Genetic Variation | 1 | 2024 | 992 | 0.040 |
Why?
| | RNA, Viral | 1 | 2023 | 691 | 0.040 |
Why?
| | Bone Density | 1 | 2022 | 492 | 0.030 |
Why?
| | Genomics | 1 | 2023 | 851 | 0.030 |
Why?
| | Europe | 1 | 2019 | 420 | 0.030 |
Why?
| | Lipids | 2 | 2017 | 715 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2021 | 1034 | 0.030 |
Why?
| | Systems Biology | 1 | 2018 | 68 | 0.030 |
Why?
| | Atmospheric Pressure | 1 | 2017 | 25 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 1 | 2023 | 2533 | 0.030 |
Why?
| | Adrenal Cortex Hormones | 1 | 2021 | 483 | 0.030 |
Why?
| | Electric Impedance | 1 | 2017 | 108 | 0.030 |
Why?
| | Exercise | 1 | 2009 | 2206 | 0.030 |
Why?
| | Electroencephalography | 1 | 2021 | 570 | 0.030 |
Why?
| | Maternal Health Services | 1 | 2019 | 99 | 0.030 |
Why?
| | Endoscopy | 1 | 2020 | 316 | 0.030 |
Why?
| | Electrocardiography | 2 | 2010 | 666 | 0.030 |
Why?
| | Total Lung Capacity | 1 | 2016 | 29 | 0.030 |
Why?
| | Diagnostic Imaging | 1 | 2019 | 340 | 0.030 |
Why?
| | Bronchial Arteries | 1 | 2016 | 12 | 0.030 |
Why?
| | Glucose | 1 | 2022 | 1051 | 0.030 |
Why?
| | Michigan | 1 | 2017 | 134 | 0.030 |
Why?
| | Causality | 1 | 2017 | 128 | 0.030 |
Why?
| | RNA | 1 | 2023 | 925 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 959 | 0.030 |
Why?
| | Area Under Curve | 1 | 2016 | 333 | 0.030 |
Why?
| | Statistics as Topic | 1 | 2016 | 277 | 0.030 |
Why?
| | Urban Population | 1 | 2019 | 496 | 0.030 |
Why?
| | Evoked Potentials, Visual | 1 | 2015 | 42 | 0.030 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2017 | 588 | 0.030 |
Why?
| | Cough | 1 | 2016 | 123 | 0.030 |
Why?
| | Automation | 1 | 2015 | 104 | 0.030 |
Why?
| | Anesthetics, Intravenous | 1 | 2015 | 67 | 0.030 |
Why?
| | Muscle Strength | 1 | 2018 | 332 | 0.030 |
Why?
| | Rats | 1 | 2023 | 5574 | 0.030 |
Why?
| | Physical Endurance | 1 | 2016 | 278 | 0.030 |
Why?
| | ROC Curve | 1 | 2016 | 613 | 0.030 |
Why?
| | Gastroesophageal Reflux | 1 | 2017 | 232 | 0.030 |
Why?
| | Cognition | 1 | 2023 | 1286 | 0.030 |
Why?
| | Child | 3 | 2025 | 22638 | 0.030 |
Why?
| | Sex Characteristics | 2 | 2014 | 798 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2017 | 507 | 0.030 |
Why?
| | Piperidines | 1 | 2015 | 223 | 0.020 |
Why?
| | Stroke | 1 | 2003 | 1283 | 0.020 |
Why?
| | Dyslipidemias | 1 | 2015 | 184 | 0.020 |
Why?
| | Hypercholesterolemia | 1 | 2014 | 95 | 0.020 |
Why?
| | Angiography | 1 | 2013 | 206 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2025 | 3917 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2019 | 3121 | 0.020 |
Why?
| | Quality Improvement | 1 | 2021 | 1325 | 0.020 |
Why?
| | Vascular Stiffness | 1 | 2017 | 488 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 326 | 0.020 |
Why?
| | Exercise Test | 1 | 2014 | 634 | 0.020 |
Why?
| | Laminectomy | 1 | 2010 | 30 | 0.020 |
Why?
| | Gene Frequency | 1 | 2011 | 495 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2015 | 2064 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 6021 | 0.020 |
Why?
| | Pyramidal Tracts | 1 | 2010 | 30 | 0.020 |
Why?
| | Internal Fixators | 1 | 2010 | 32 | 0.020 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2010 | 121 | 0.020 |
Why?
| | Median Nerve | 1 | 2009 | 26 | 0.020 |
Why?
| | Thoracic Vertebrae | 1 | 2010 | 90 | 0.020 |
Why?
| | Neural Tube Defects | 1 | 2010 | 67 | 0.020 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2016 | 639 | 0.020 |
Why?
| | Facial Paralysis | 1 | 2009 | 22 | 0.020 |
Why?
| | Functional Laterality | 1 | 2010 | 240 | 0.020 |
Why?
| | Intra-Abdominal Fat | 1 | 2010 | 101 | 0.020 |
Why?
| | Artifacts | 1 | 2009 | 142 | 0.020 |
Why?
| | Observer Variation | 1 | 2009 | 355 | 0.020 |
Why?
| | Personality Inventory | 1 | 2009 | 132 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2010 | 452 | 0.020 |
Why?
| | Age Factors | 2 | 2007 | 3321 | 0.020 |
Why?
| | Diabetic Neuropathies | 1 | 2009 | 100 | 0.020 |
Why?
| | Health Surveys | 1 | 2009 | 511 | 0.020 |
Why?
| | Algorithms | 1 | 2015 | 1843 | 0.020 |
Why?
| | Angiotensins | 1 | 2007 | 8 | 0.020 |
Why?
| | Scoliosis | 1 | 2010 | 230 | 0.020 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2007 | 25 | 0.020 |
Why?
| | Contraceptive Agents, Female | 1 | 2008 | 80 | 0.020 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2007 | 57 | 0.020 |
Why?
| | Postoperative Complications | 2 | 2010 | 2962 | 0.020 |
Why?
| | Electromyography | 1 | 2009 | 417 | 0.020 |
Why?
| | Preoperative Care | 1 | 2009 | 375 | 0.020 |
Why?
| | Diabetic Retinopathy | 1 | 2009 | 211 | 0.010 |
Why?
| | Patient Selection | 1 | 2010 | 720 | 0.010 |
Why?
| | Self Care | 1 | 2009 | 396 | 0.010 |
Why?
| | Amino Acid Substitution | 1 | 2006 | 295 | 0.010 |
Why?
| | Waist-Hip Ratio | 1 | 2004 | 37 | 0.010 |
Why?
| | Platelet Aggregation | 1 | 2005 | 99 | 0.010 |
Why?
| | Radiography, Abdominal | 1 | 2004 | 44 | 0.010 |
Why?
| | Age Distribution | 1 | 2005 | 395 | 0.010 |
Why?
| | Anthropometry | 1 | 2004 | 203 | 0.010 |
Why?
| | Feeding Behavior | 1 | 2009 | 691 | 0.010 |
Why?
| | Alleles | 1 | 2006 | 900 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2005 | 1160 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2006 | 1236 | 0.010 |
Why?
| | Risk | 1 | 2003 | 917 | 0.010 |
Why?
| | Neoplasms | 1 | 2016 | 2944 | 0.010 |
Why?
| | Hyperglycemia | 1 | 2003 | 381 | 0.010 |
Why?
| | DNA | 1 | 2006 | 1418 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2006 | 1367 | 0.010 |
Why?
| | Hypoglycemic Agents | 1 | 2005 | 1411 | 0.010 |
Why?
|
|
Kinney's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|